What is Tagrisso?
This medication is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.
How does Xalkori work?
Crizotinib works by targeting and blocking receptors found on the cancer cells called an anaplastic lymphoma kinase (ALK). In some cancers, this receptor is overactive, causing cells to grow and divide too fast. By inhibiting ALK, this medication can slow or stop cell growth of cancer cells.
How effective is Xalkori?
Results showed 66 percent of participants experienced a complete or partial shrinkage of their NSCLC tumors, an effect that lasted a median of 18.3 months. The safety results of this study were generally consistent with the safety profile of Xalkori evaluated in 1,669 patients with ALK-positive metastatic NSCLC.
When was crizotinib first approved?
On March 11, 2016, the U. S. Food and Drug Administration approved crizotinib capsules (Xalkori, Pfizer, Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
Is Tagrisso a targeted therapy?
*For tumors with EGFR exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. TAGRISSO is the #1 prescribed EGFR TKI therapy as a first treatment.
What lung problems does Tagrisso cause?
This medicine may cause swelling of the lungs (pneumonitis) or interstitial lung disease. These are life-threatening conditions and require immediate medical attention. The symptoms may be similar to the symptoms from lung cancer.
How long does Xalkori take to work?
The median duration of study treatment was 10.9 months for patients in the XALKORI arm and 4.1 months for patients in the chemotherapy arm. Median duration of treatment was 5.2 months for patients who received XALKORI after cross over from chemotherapy.
What is Xalkori used to treat?
XALKORI is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1.
Can crizotinib (Xalkori®) help patients with advanced lung cancer?
Results from an international phase III trial show that crizotinib (Xalkori®) may benefit previously treated patients with advanced lung cancer whose tumors have a specific genetic mutation. The targeted therapy substantially extended the amount of time trial participants lived without their disease getting worse.
What follow-up ophthalmologic examination is required after taking Xalkori?
Follow-up ophthalmologic examination including retinal examination is recommended within 1 month of starting XALKORI, every 3 months thereafter, and upon any new visual symptoms. Assessment of visual symptoms is recommended monthly during treatment. Report any visual symptoms to an eye specialist.